05.09.2022 • News

Technip Energies Buys DSM’s Biosuccinium Technology

French engineering and technology company Technip Energies has boosted its sustainable chemicals portfolio with the purchase of DSM’s biosuccinium technology. Financial terms were not disclosed.

Technip said it will be the only technology licensed on the market for producing bio-based succinic acid, which is a feedstock for manufacturing polybutylene succinate (PBS), a sustainable packaging material for food contact applications.

“This addition to our growing sustainable chemicals portfolio will allow Technip Energies to license a solution for the production of a bio-sourced and biodegradable polymer, which has a 50% lower carbon footprint compared to fossil-based routes,” said Bhaskar Patel, senior vice president, sustainable fuels, chemicals and circularity at Technip Energies. “Superior product properties, combined with best-in-class sustainability performance, are key attributes in today’s consumer market. We shall leverage the whole PBS value chain, where we already license the technology for the polymerization of the bio-sourced monomers into PBS.”

The purchase includes a wide range of patent families and proprietary yeast strains, which Technip said have been demonstrated in large-scale production facilities.

DSM originally developed biosuccinium as part of Reverdia, a joint venture with Roquette that was dissolved on Apr. 1, 2019. DSM retained exclusive licensing rights to the technology.

Author: Elaine Burridge, Freelance Author

© Shutterstock
© Shutterstock

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read